Active Biotech AB announced the approval for tasquinimod Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of myelofibrosis. It creates an important regulatory channel and gives us the opportunity to rapidly progress tasquinimod development in this patient population.
Incyte has announced to receive data from two Limber trials assessing single-agent therapy and combination treatments in patients with myelofibrosis (MF) using ruxolitinib with parsaclisib.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5044
Published Date: Jun 17, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing cases of essential thrombocythemia, and rising investment in research development of new drugs are the major factors driving the market growth.
The market size of essential thrombocythemia is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Incyte, Bayer AG, Merck & Co., Inc.., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited., and Active Biotech AB.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment type, end user, and by region.
The hydroxyurea segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Lack of treatment, underdiagnosis and misdiagnosis, and slow clinical trials are estimated to be the growth-hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.